Evidence map›Paper›PMID 41063766›Full record

ArticleBreast care (Basel, Switzerland)2026

Advanced Glycation End Products: A Promising Prognostic Indicator in Breast Cancer Patients.

Gülcin Sahingoz Erdal, Nilgun Isiksacan, Murat Cikot, Mustafa Yaman, Esra Yildirim Servi, Elif Ede Cintosun, Sevgi Kalkanli Tas, Tamay Seda Tasci, Nursel Kocamaz, Dilay Karabulut

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast care (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Gülcin Sahingoz ErdalDepartment of Oncology, University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
Nilgun IsiksacanDepartment of Immunology, University of Health Sciences, Istanbul, Turkey.
Murat CikotDepartment of General Surgery, University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
Mustafa YamanDepartment of Molecular Biology and Genetics, Faculty of Health Sciences, Istanbul Sabahattin Zaim University, Istanbul, Turkey.
Esra Yildirim ServiDepartment of Molecular Biology and Genetics, Faculty of Health Sciences, Istanbul Sabahattin Zaim University, Istanbul, Turkey.
Elif Ede CintosunDepartment of Nutrition and Dietetics, Faculty of Health Sciences, Istanbul Sabahattin Zaim University, Istanbul, Turkey.
Sevgi Kalkanli TasDepartment of Immunology, University of Health Sciences, Istanbul, Turkey.
Tamay Seda TasciDepartment of Immunology, University of Health Sciences, Istanbul, Turkey.
Nursel KocamazDepartment of Internal Medicine, University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
Dilay KarabulutDepartment of Cardiology, University of Health Sciences, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Advanced glycation end products (AGEs) form through long-term reactions between proteins/lipids and sugars, accumulating in tissues and contributing to disease. AGEs are linked to cancer progression, with studies showing associations with colon and pancreatic cancer. Methods: This study investigates the relationship between AGEs and breast cancer. Stage 2-3 breast cancer patients and age-matched healthy controls were included. Exclusion criteria were diabetes, renal/liver disease, chronic inflammation, and infection. Blood samples were collected from patients pre-surgery and 48 h post-surgery and once from fasting controls. Glyoxal (GO) and methylglyoxal (MGO) levels were measured via liquid chromatography. A total of 60 breast cancer patients and 21 controls participated. Results: GO and MGO levels were significantly higher in patients than controls ( Conclusion: The significant drop in AGE levels post-surgery suggests tumor burden influences AGE levels. While their predictive value remains uncertain, AGEs could serve as prognostic biomarkers. Monitoring AGEs may encourage lifestyle changes, and rising levels might indicate cancer recurrence or progression.

Indexed as

Advanced glycation end productsBiomarkerBreast cancerPrognosis

Identifiers

PMID41063766
PMCPMC12503891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.